Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05730218 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment
A Phase 2 study, sponsored by ONL Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT05730218 is a Phase 2 study that has completed, run by ONL Therapeutics. The registered enrollment target is 136 participants.
The verdict
NCT05730218, a Phase 2 study, has completed, sponsored by ONL Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
The goal of this Phase 2 clinical trial is to learn about ONL1204 Ophthalmic Solution in terms of safety and how well the drug works in patients that have a macula-off (central point of vision) rhegmatogenous retinal detachment (RRD). The main questions it aims to answer are: * Does ONL1204 improve vision in macula-off RRD patients when used before retinal detachment repair surgery compared to patients that have surgery alone? * Is ONL1204 safe to use as an add-on drug before retinal repair surgery? Researchers will observe patients that receive two different dosages of ONL1204 Ophthalmic Solution (50 µg or 200 µg) compared to current standard therapy (no treatment) to see if there are differences in vision and safety outcomes.
Interventions
- DRUG Sham treatment
- DRUG ONL1204 Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2023-04-04 |
| Est. Completion | 2024-02-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05730218
The ClinicalTrials.gov registry entry for NCT05730218 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ONL Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham treatment is the first listed.
NCT05730218 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05730218 about?
NCT05730218 is a clinical study titled "A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment". The goal of this Phase 2 clinical trial is to learn about ONL1204 Ophthalmic Solution in terms of safety and how well the drug works in patients that have a macula-off (central point of vision) rhegmatogenous retinal detachment (RRD). The main questions it aims to answer are: * Does ONL1204 improve...
What is the current status of trial NCT05730218?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2023-04-04. Estimated completion is 2024-02-21.
What interventions are being tested in trial NCT05730218?
The interventions under investigation include: Sham treatment (DRUG), ONL1204 Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT05730218?
This trial is sponsored by ONL Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.